V-Card | Print | PDF | Email Page

Anthony M. Insogna
Partner

Practice Leader Intellectual Property

Contact

(T) +1.858.314.1130
(F) +1.844.345.3178

Education

  • Fordham University (J.D. 1994); New York University (M.S. in Organic Chemistry 1990; B.S. in Organic Chemistry 1989)

Bar Admissions

  • New York, District of Columbia, California, U.S. Supreme Court, U.S. Court of Appeals for the Federal Circuit, U.S. District Courts for the Southern District of California and Eastern and Southern Districts of New York, and registered to practice before the U.S. Patent and Trademark Office

Anthony Insogna is the Chair of Jones Day's global IP Practice and is a leading pharmaceutical and biotechnology patent lawyer as recognized by clients, Chambers, and his peers. He has more than 25 years of experience enforcing and defending patents around the globe, driving patent portfolio strategy, and conducting due diligence for transactions and financings involving life sciences companies, investment banks, and venture capital firms.

Since 2012, Anthony has navigated Idenix (Merck & Co.) in global battles culminating in the 2016 record-breaking $2.54B patent infringement verdict. He and his teams successfully defended patents involving Humira® (involving two IPRs brought by Amgen and five separate IPRs brought by Coherus) and Revlimid®, the No. 1 and No. 6 top-selling drugs of 2016, respectively, before the PTAB.

Anthony's patent strategies have protected several multibillion and multimillion dollar drugs. He has been counsel to Celgene, now the world's leading hematology and oncology company, since 1996. Further his IP strategies have been tested in litigation and M&A transactions, e.g., including Merck's $3.85B acquisition of Idenix, Dainippon Sumitomo Pharma's $2.6B acquisition of Sepracor, Pfizer's $1.3B acquisition of Esperion, Amgen's $1.3B acquisition of Tularik, J&J's $970M acquisition of Cougar Biotechnology, MedImmune's $492M acquisition of U.S. Bioscience, and Merit Medical's $100M acquisition of BioSphere Medical.

Additional products for which Anthony has experience with litigation, prosecution, interferences, oppositions, invalidation actions, or transactions include: Abraxane®, Allegra®, Brovana®, Clarinex®, Clofar®, Embospheres®, Ethyol®, Focalin®, Focalin XR®, HepaSpheres®, Ingrezza, Istodax®, Kuvan®, Lunesta®, Nesina®, Nithiodote®, Nuplazid®, Otezla®, Pristiq®, Pomalyst®, Relafen®, Rezield, Ritalin LA®, Synagis®, Thalomid®, Tyzeka®, Vidaza®, Xyrem®, and Zytiga®.

Anthony founded the Firm's San Diego Office in 2004.


Honors & Distinctions

  • Chambers: Band 1 (2015-2017)

    Legal 500 US: (2011-2017; elite leading lawyer, 2017)

    World IP Review (leader, 2016-2017)

    Best Lawyers in America: Biotechnology Lawyer of the Year (2017); San Diego Patent Lawyer of the Year (2015)

    IAM Patent 1000 (2014-2017)

    Managing IP: IP Star (2014-2017)

    Daily Journal: Top IP Attorneys in California (2015-2017)

    Daily Transcript: Top Influentials (2017); Top 100 Business Professionals (2016)
Anthony Insogna